126 related articles for article (PubMed ID: 31764258)
1. Insights for Implementation Science From 2 Multiphased Studies With End-Users of Potential Multipurpose Prevention Technology and HIV Prevention Products.
Minnis AM; Montgomery ET; Napierala S; Browne EN; van der Straten A
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 3():S222-S229. PubMed ID: 31764258
[TBL] [Abstract][Full Text] [Related]
2. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
[TBL] [Abstract][Full Text] [Related]
3. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
Minnis AM; Roberts ST; Agot K; Weinrib R; Ahmed K; Manenzhe K; Owino F; van der Straten A;
AIDS Behav; 2018 Aug; 22(8):2662-2673. PubMed ID: 29560570
[TBL] [Abstract][Full Text] [Related]
4. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study.
Montgomery ET; Beksinska M; Mgodi N; Schwartz J; Weinrib R; Browne EN; Mphili N; Musara P; Jaggernath M; Ju S; Smit J; Chirenje ZM; Doncel GF; van der Straten A
J Int AIDS Soc; 2019 May; 22(5):e25283. PubMed ID: 31069957
[TBL] [Abstract][Full Text] [Related]
5. End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.
Weinrib R; Minnis A; Agot K; Ahmed K; Owino F; Manenzhe K; Cheng H; van der Straten A
AIDS Behav; 2018 Jan; 22(1):133-145. PubMed ID: 29052018
[TBL] [Abstract][Full Text] [Related]
6. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.
Minnis AM; Atujuna M; Browne EN; Ndwayana S; Hartmann M; Sindelo S; Ngcwayi N; Boeri M; Mansfield C; Bekker LG; Montgomery ET
J Int AIDS Soc; 2020 Jun; 23(6):e25528. PubMed ID: 32544303
[TBL] [Abstract][Full Text] [Related]
7. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
[TBL] [Abstract][Full Text] [Related]
8. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
[TBL] [Abstract][Full Text] [Related]
9. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
[TBL] [Abstract][Full Text] [Related]
10. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
[TBL] [Abstract][Full Text] [Related]
11. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
[TBL] [Abstract][Full Text] [Related]
12. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
[TBL] [Abstract][Full Text] [Related]
13. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
[TBL] [Abstract][Full Text] [Related]
14. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
[TBL] [Abstract][Full Text] [Related]
15. Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.
Weinrib R; Browne EN; Shapley-Quinn MK; van der Straten A; Beksinska M; Mgodi N; Musara P; Mphili N; Schwartz JL; Ju S; Hanif H; Montgomery ET;
AIDS Behav; 2020 Feb; 24(2):637-647. PubMed ID: 31254190
[TBL] [Abstract][Full Text] [Related]
16. Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe: Qualitative Findings.
Musara P; Milford C; Shapley-Quinn MK; Weinrib R; Mutero P; Odoom E; Mgodi NM; Chirenje ZM; Hanif H; Clark MR; Smit J; van der Straten A; Montgomery ET;
AIDS Behav; 2021 Jan; 25(1):124-138. PubMed ID: 32588257
[TBL] [Abstract][Full Text] [Related]
17. Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa.
Minnis AM; Krogstad E; Shapley-Quinn MK; Agot K; Ahmed K; Danielle Wagner L; van der Straten A;
Sex Reprod Health Matters; 2021 Dec; 29(1):1927477. PubMed ID: 34224341
[TBL] [Abstract][Full Text] [Related]
18. Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya.
Wagner LD; Minnis AM; Shea J; Agot K; Ahmed K; van der Straten A
PLoS One; 2022; 17(5):e0265303. PubMed ID: 35551318
[TBL] [Abstract][Full Text] [Related]
19. Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment.
Browne EN; Montgomery ET; Mansfield C; Boeri M; Mange B; Beksinska M; Schwartz JL; Clark MR; Doncel GF; Smit J; Chirenje ZM; van der Straten A
AIDS Behav; 2020 May; 24(5):1443-1451. PubMed ID: 31696371
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
